About Kedrion
Kedrion is a company based in Barga (Italy) founded in 2001 was acquired by Permira in January 2022. Kedrion has raised $188.56 million across 3 funding rounds from investors including Permira, CDP Equity and IMI Fondi Chiusi SGR. Kedrion operates in a competitive market with competitors including Moderna, CareDx, Forge Biologics, Editas Medicine and Annexon, among others.
- Headquarter Barga, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kedrion Biopharma India Private Limited
- Date of Incorporation 06 Dec, 2013
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$4.32 M (USD)17.9as on Mar 31, 2020
-
Net Profit
-$957.81 K (USD)-143.53as on Mar 31, 2020
-
EBITDA
-$1.61 M (USD)-79.73as on Mar 31, 2020
-
Total Equity Funding
$188.56 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Permira
& 3 more
-
Employee Count
Not available
-
Acquired by
Permira
(Jan 20, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Kedrion
Unlock access to complete
Software Development Team
55 people
Leadership Team
29 people
Human Resources and Administration
14 people
Sales and Marketing
13 people
Senior Team
9 people
Legal and Compliance
9 people
Operations Team
9 people
Product Management Team
8 people
Unlock access to complete
Funding Insights of Kedrion
Kedrion has successfully raised a total of $188.56M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kedrion
Kedrion has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Permira, CDP Equity and IMI Fondi Chiusi SGR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm focused on buyouts
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made in technology, consumer, healthcare, and service sectors.
|
Locked | Locked | Locked |
Investor details for Kedrion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kedrion
Investment portfolio details for Kedrion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kedrion
Detailed financials for Kedrion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kedrion Comparisons
Peer comparison for Kedrion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kedrion
Kedrion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, CareDx, Forge Biologics, Editas Medicine and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Kedrion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kedrion
Complete news archive for Kedrion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kedrion
Kedrion was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Kedrion is headquartered in Barga, Italy. It is registered at Barga, Tuscany, Italy.
Kedrion is a funded company, having raised a total of $188.56M across 3 funding rounds to date.
Annual revenue of Kedrion is $4.32M as on Mar 31, 2020.
Founded in 2001 and headquartered in Barga, Italy, Kedrion operates in the biotechnology sector. Blood plasma is collected and fractionated to produce therapies addressing hemophilia, immune system deficiencies, and critical care needs, including Albumin and Anti-D Immunoglobulin (RhoGAM) for preventing hemolytic disease in newborns. Efforts are focused on expanding the pipeline in hematology, immunology, and critical care areas.
Kedrion has 4 investors. Key investors include Permira, CDP Equity, IMI Fondi Chiusi SGR, and Marcucci family.